Wedbush Downgrades Passage Bio to Neutral, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 90.6%

Neg 90.6% Neu 0% Pos 0%

Wedbush analyst Yun Zhong downgrades Passage Bio (NASDAQ:PASG) from Outperform to Neutral and lowers the price target from $32 to $8.